Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients A Pragmatic Trial (EVOLUTION).

Brief description of study

This research study is being conducted to determine whether switching to an IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) for patients with psoriatic arthritis (PsA) who had an inadequate response to a TNFi (tumor necrosis factor inhibitor).

Guselkumab and Golimumab are prescription medicines that have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of active psoriatic arthritis in adults. You may be eligible to receive the medication without participation in this study.

This study will also investigate whether determine whether more frequent dosing of GUS (every 4 weeks), a higher dose than the currently approved dose, is more effective than GUS every 8 weeks (the currently approved dosing).

Clinical Study Identifier: s23-00181
Principal Investigator: Soumya M Reddy.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.